Cerebrotendinous xanthomatosis (CTX): A treatable lipid storage disease: A treatable lipid storage disease

Zohar Keren, Tzipora C. Falik-Zaccai

Research output: Contribution to journalArticlepeer-review

26 Scopus citations

Abstract

Cerebrotendinous xanthomatosis (CTX) is a rare autosomal recessive lipid storage disease with multi-organ involvement. The clinical manifestations usually start at infancy and develop during the first and second decades of life; infantile-onset diarrhea may be the earliest clinical manifestation of CTX. Additional clinical manifestations are juvenile cataracts, tendon xanthomas, and multiple progressive neurological symptoms. Systemic manifestations that are often found include osteoporosis, heart involvement and premature arteriosclerosis. CTX is caused by mutations in the sterol 27 hydroxylase gene (CYP27) on chromosome 2q35-qter, which is responsible for conversion of cholesterol to cholic and chenodeoxycholic acid. Reduced synthesis of cholic and chenodeoxycholic acid results in failed feedback inhibition of cholesterol production, which in turn leads to increased serum cholestanol concentration and elevated urinary bile alcohols. Early treatment with chenodeoxycholic acid (CDCA) prevents the clinical symptoms and prevents deterioration. Although CTX is rare world wide, genetic islands of high frequency have been reported. In this review we would like to familiarize the reader with this fatal inborn error of metabolism that is possibly under-diagnosed and is preventable once recognized and treated.
Original languageEnglish
Pages (from-to)6-11
Number of pages6
JournalPediatric Endocrinology Reviews
Volume7
Issue number1
StatePublished - 1 Sep 2009

Keywords

  • CDCA
  • Cerebrotendinous xanthomatosis
  • Lipid storage disease
  • Sterol 27 hydroxylase

Fingerprint

Dive into the research topics of 'Cerebrotendinous xanthomatosis (CTX): A treatable lipid storage disease: A treatable lipid storage disease'. Together they form a unique fingerprint.

Cite this